GE Healthcare has completed a license agreement with NorDiag, allowing the Bergen, Norway-based company access to GE's patents for the biomagnetic isolation of nucleic acids.
The pact also allows NorDiag to use GE Healthcare's proprietary magnetic separation technology, which is designed to isolate and purify biomolecules, such as DNA and RNA, from laboratory and clinical samples. The protocols from Chalfont St. Giles, U.K.-based GE allow diagnosis from smaller-volume patient samples, because they increase the yield of nucleic acid from disease-causing pathogens isolated from patient samples.
By AuntMinnie.com staff writers
May 3, 2007
Related Reading
Regents picked for GE consulting program, May 3, 2007
GE unveils new CT contrast injector, May 2, 2007
GE gets nod for VCAR for PET, April 20, 2007
GE Healthcare posts higher Q1 profit on flat sales, April 17, 2007
GE taps Kramer, April 17, 2007
Copyright © 2007 AuntMinnie.com
